AfterRaise/Companies/Sling Therapeutics

Sling Therapeutics

$123M Series CRaised yesterdayAnn Arbor, USABiotech & PharmaUSA

Why now

Where Sling Therapeutics is today

Sling Therapeutics announced a Series C round of $123M on 16 September 2026, led by Forbion.

Latest round
Series C
Amount
$123M
Announced
16 September 2026
Headquarters
Ann Arbor, USA
Sector
Biotech & Pharma
Growth stage
Series C+
Investors
Forbion
Also participating
existing investor TPG Life Sciences Innovations and new investor Sectoral Asset Management
Relevant leadership
Not stated

Momentum AfterRaise intelligence

AfterRaise Score

82
High momentum
1 funding signal in the last 90 days
Funding recency
40/40
announced within the last 30 days
Round scale
22/25
round size relative to the market
Funding stage
20/20
Series C
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

In their own words

What Sling Therapeutics says it is doing

Work here? Reserve your page

Public signal Described in the funding announcement as "clinical-stage biopharmaceutical company developing the first and only late-stage oral small-molecule therapy for thyroid eye disease (TED)". Source

Research and development

Public signal Read from the company's own description of what the funding supports.

Since the raise

What has happened since

  • 16 September 2026
    $123M Series C
    Led by Forbion.

Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

What may happen next

What this raise could create

AfterRaise intelligenceNot a statement of fact

What may happen next

  • Research programme expansion
  • Scientific team growth
  • Aggressive multi-front expansion
  • Senior executive hiring

Opportunities this could create

  • Clinical operations
  • Scientific hiring
  • Scientific advisers
  • Research operations
  • Specialist suppliers

Based on the Biotech & Pharma sector, a Series C+ round and the priorities the company itself set out. Not a statement of fact.

Medium momentum2 connected signals
  • 16 September 2026$123M Series C announced
  • 16 September 2026Stated priority: research and development

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Open to

What Sling Therapeutics is open to

Not yet specified

Sling Therapeutics has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Opportunities

Ways to work with Sling Therapeutics

No open opportunities listed

Jobs, projects, partnerships, advisory and supplier needs appear here once the company has claimed its page and published them, and any role we read from its own job board appears automatically.

Work here? Open the first one

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Do you work at Sling Therapeutics?

Reserve your company page.

This page was created from publicly available information. When verified company accounts open, your team will be able to correct your profile, tell the market what you actually need and control how people approach you.

What we do not have yet: your website, the roles and projects you have open and who leads the team. Claiming the page is how you fill those in.

Someone else requesting access does not give them ownership. Every company administrator is verified before access is granted.

The first 1,000 verified funded companies join the Founding 1,000 free for life and keep Founding Company status permanently.

Also moving

Other Biotech & Pharma companies

See the sector